Literature DB >> 22008610

Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65.

M S Hunter1, A Gentry-Maharaj, A Ryan, M Burnell, A Lanceley, L Fraser, I Jacobs, U Menon.   

Abstract

OBJECTIVE: Hot flushes and night sweats (HFs/NSs) are the main menopausal symptoms, but few studies have been adequately powered to examine the dimensions or predictors of experiencing HFs/NSs. We report on these variables in a large UK cohort of postmenopausal women.
DESIGN: Cross-sectional cohort study.
SETTING: UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) cohort. POPULATION: A cohort of 202,638 postmenopausal women, aged 50-74 years, without oophorectomy, recruited to UKCTOCS between 2001 and 2005.
METHODS: Women completed a follow-up questionnaire, and those aged 54-65 years were mailed a survey in July 2008. MAIN OUTCOME MEASURES: Hot flush prevalence and hot flush rating scale.
RESULTS: Of the 15,000 women mailed, 10,418 returned completed questionnaires; 90% had previously had HFs/NSs. Despite being on average 10 years postmenopausal, 54% experienced HFs/NSs (frequency of 33 per week with mean problem rating 4/10) that persisted across the age range. Past hysterectomy (OR 1.50, 95% CI 1.19-1.86), ever having smoked (OR 1.27, 95% CI 1.11-1.46) and alcohol consumption (current units) (OR 1.05, 95% CI 1.01-1.09) predicted ever having had HFs/NSs. Anxiety (OR 3.09, 95% CI 2.57-3.72), hysterectomy (OR 2.74, 95% CI 2.32-3.25), depressed mood (OR 1.57, 95% CI 1.24-1.99), years since last menstrual period (OR 0.95, 95% CI 0.94-0.96) and education (above and below 18 years) (OR 0.98, 95% CI 0.97-0.99) predicted the current prevalence of HFs/NSs. Few predictors of frequency were identified, but problem rating was associated with depressed mood, hysterectomy, skirt size increase and frequency of HFs/NSs. Past hormone therapy users who had discontinued treatment were more likely to have HFs/NSs that were more frequent and problematic.
CONCLUSIONS: To date, this is the largest UK study of the experience of HFs/NSs amongst older postmenopausal women. HFs/NSs are more prevalent in this age band than has previously been assumed. These findings and the associations of smoking, hysterectomy, anxiety, depressed mood and hormone therapy use with the experience of HFs/NSs have implications for prevention and symptom management.
© 2011 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2011 RCOG.

Entities:  

Mesh:

Year:  2011        PMID: 22008610     DOI: 10.1111/j.1471-0528.2011.03166.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  26 in total

Review 1.  Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.

Authors:  Nancy E Avis; Sybil L Crawford; Robin Green
Journal:  Obstet Gynecol Clin North Am       Date:  2018-10-25       Impact factor: 2.844

2.  A potentially functional variant in the serotonin transporter gene is associated with premenopausal and perimenopausal hot flashes.

Authors:  May E Montasser; Ayelet Ziv-Gal; Jessica P Brown; Jodi A Flaws; Istvan Merchenthaler
Journal:  Menopause       Date:  2015-01       Impact factor: 2.953

3.  Characterizing the trajectories of vasomotor symptoms across the menopausal transition.

Authors:  Ping G Tepper; Maria M Brooks; John F Randolph; Sybil L Crawford; Samar R El Khoudary; Ellen B Gold; Bill L Lasley; Bobby Jones; Hadine Joffe; Rachel Hess; Nancy E Avis; Sioban Harlow; Daniel S McConnell; Joyce T Bromberger; Huiyong Zheng; Kristine Ruppert; Rebecca C Thurston
Journal:  Menopause       Date:  2016-10       Impact factor: 2.953

4.  A Comprehensive Method To Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B Receptor Agonist Senktide.

Authors:  Ashley A Krull; Sarah A Larsen; Donald K Clifton; Genevieve Neal-Perry; Robert A Steiner
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

5.  Stellate ganglion blockade and verbal memory in midlife women: Evidence from a randomized trial.

Authors:  Pauline M Maki; Leah H Rubin; Antonia Savarese; Lauren Drogos; Lee P Shulman; Suzanne Banuvar; David R Walega
Journal:  Maturitas       Date:  2016-07-17       Impact factor: 4.342

Review 6.  Risk factors, pathophysiology, and treatment of hot flashes in cancer.

Authors:  William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter
Journal:  CA Cancer J Clin       Date:  2013-01-25       Impact factor: 508.702

7.  Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study.

Authors:  Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Clara Glazer; Matthew Burnell; Andy Ryan; Lindsay Fraser; Anne Lanceley; Ian Jacobs; Myra S Hunter; Usha Menon
Journal:  Menopause       Date:  2015-04       Impact factor: 2.953

8.  The effect of physical activity and body mass index on menopausal symptoms in Turkish women: a cross-sectional study in primary care.

Authors:  Makbule Neslisah Tan; Mehtap Kartal; Dilek Guldal
Journal:  BMC Womens Health       Date:  2014-03-06       Impact factor: 2.809

9.  A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.

Authors:  Juergen Drewe; Kathleen A Bucher; Catherine Zahner
Journal:  Springerplus       Date:  2015-02-10

10.  Dose-Dependent Effects of the Cimicifuga racemosa Extract Ze 450 in the Treatment of Climacteric Complaints: A Randomized, Placebo-Controlled Study.

Authors:  Ruediger Schellenberg; Reinhard Saller; Lorenzo Hess; Jörg Melzer; Christian Zimmermann; Juergen Drewe; Catherine Zahner
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.